Diary - News
All news Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development
Lyon, France – 17 December 2020: Novadiscovery, a leading health tech company offering a best-inclass clinical trial simulation platform, Jinkō®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline.
Novadiscovery is committed to working with forward-looking industry leaders to improve R&D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials.
Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve clinical trial efficiency and increase the probability of regulatory success.
